Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3115A1-303-WW.

Trial Profile

Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3115A1-303-WW.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Conjugated estrogens/bazedoxifene (Primary) ; Raloxifene
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 24 Mar 2011 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 31 Aug 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 31 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top